^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Rectal Cancer
    Drug:Jemperli (dostarlimab-gxly) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Rectal Cancer...SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE-CHEMOTHERAPY REGIMENS...Dostarlimab-gxly (dMMR/MSI-H only)
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Solid Tumor)
    New
    Excerpt:
    JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced...solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

    Excerpt:
    ...- Participant has a tumor which can be categorized as dMMR or MSI-H by local or central assessment...
    Trial ID:
    AZUR-1
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Phase 2 Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer Estudio de fase II de dostarlimab en pacientes con cáncer de recto dMMR/MSI-H localmente avanzado no tratado previamente

    Excerpt:
    ...Inclusion criteria (Prescreening Period)- A Prescreening Period will only be available at sites/countries where local dMMR/MSI-H testing is not available. ...
    Trial ID:
    2022-003289-18